Sanofi’s rimonabant from A to Z

The Endocrinologic and Metabolic Drugs Advisory Committee will convene June 13 to discuss efficacy and safety data for Sanofi-Aventis' potential first-in-class obesity agent rimonabant. The proposed trade name for the CB-1 receptor agonist, previously known as Acomplia in the U.S., is Zimulti. The committee will review rimonabant's use as an adjunct to diet and exercise for obesity management in patients. Sanofi announced in February that FDA extended rimonabant's user fee date by three months, which would set a late July user fee action date (1"The Pink Sheet" Feb. 19, 2007, p. 19). The meeting will take place at the Hilton in Silver Spring, Md., from 8 a.m. to 5 p.m...